A Phase II, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy of Partuzumab (rhuMAb 2C4) in Combination with Gencitabine

Grants and Contracts Details

StatusFinished
Effective start/end date6/1/0512/31/07

Funding

  • Genentech Inc: $282,961.00